AMDL Announces Teleconference to Discuss Its Second Quarter 2008 Financial Results
Existing or potential investors who would like to submit questions priorto the call can do so by emailing Kristine Szarkowitz at email@example.com.
To access the live call, please dial (877) 360-1705 in the U.S. or(706) 902-3245 outside the U.S. and reference Conference ID# 60855707 fiveminutes before the call begins. The conference call script will also beavailable on the Investor section of the AMDL web site located athttp://www.amdl.com. Click on "Investor Relations," then "Recent News" toaccess the Company's earnings release which was issued today, August 15, 2008,and all other accompanying financial and operating information.
AMDL Inc. is a global specialty pharmaceutical company. The company isheadquartered in Tustin, California with operations in Shenzhen, Jiangxi, andJilin, China. Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDLis devoted to the research, development, manufacture, and marketing ofdiagnostic, pharmaceutical, nutritional supplement, and cosmetic productscurrently in China. The company employs approximately 320 people in the U.S.and China. More information about AMDL and its products can be obtained athttp://www.amdl.com.
About Jade Pharmaceutical:
JPI has access to the fastest growing pharmaceutical and consumer marketin the world -- China. AMDL, through its Jade subsidiaries, currently holdslicenses for 133 products that are manufactured as large volume injectionfluids, tablets and other related products. It currently manufactures over 20key generic, over-the-counter and supplemental pharmaceutical products undercertified Chinese Good Manufacturing Practice (CGMP) standards.AMDL Contact: Kristine Szarkowitz Director-Investor Relations firstname.lastname@example.org (M) (206) 310-5323
You May Also Like